Author: Customer Service

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio – – Lorundrostat demonstrated a favorable safety profile in participants with and without chronic kidney disease over 12 weeks – RADNOR, Pa., May 30, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today presented new clinical data for lorundrostat at the 35th European...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. ASCO takes place May 29-June 2 in Chicago, and SNMMI May 30-June 2 in Los Angeles. MP0712 is a 212Pb-based Radio-DARPin Therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3)...

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting. “The overall survival analysis from IGNYTE shows that nearly half of all treated patients in the study were alive at three years, including 83.5% of responders to RP1 plus nivolumab,” said Kostas Xynos, MD, PhD, MBA, Chief Medical Officer of Replimune. “This represents a durable benefit that is rarely seen in anti-PD-1-failed melanoma, a setting with historically limited treatment options.” Key findings are detailed...

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete responses, and longest ongoing response at 12 monthsAdditional Phase 1 data for IMA203CD8 in heavily pretreated patients with synovial sarcoma showed deep and durable responses with a 67% ORR and 64% cORR, including one complete response, and ongoing responses up to ~3 yearsIMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populationsClinical anti-tumor activity observed across tumor types (ovarian carcinoma, uterine cancer, melanoma, synovial sarcoma) with distinct biology and differing levels of PRAME expression,...

Reference is made to the stock exchange notice dated 1 April 2026 and previous notices regarding the petition by DNB Bank ASA, Swedbank AB (publ) og Danske Bank A/S NUF to register arrest in certain assets of the group. Borgarting Court of Appeal issued its ruling on Friday 29 May.  The Banks petition for arrest has been dismissed by the court. ContactsChief Executive Officer Njål Sævik, +47 909 35 722Chief Financial Officer Arne Johan Dale, +47 909 87 706This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

VANCOUVER, BC, May 29, 2026 (GLOBE NEWSWIRE) — Fobi” or the “Company”), a leader in AI powered data intelligence and digital wallet solutions, today provided an update regarding the status of the Company’s ongoing efforts in connection with the revocation of the existing failure to file cease trade order (“FFCTO”) and the resumption of trading of the Company’s common shares on the TSX Venture Exchange (the “TSXV”). The Company confirms that it continues to work diligently and cooperatively with both the British Columbia Securities Commission (“BCSC”) and the TSXV in connection with the FFCTO revocation process and the Company’s application for reinstatement of trading. Fobi further announces that it has completed its Q3 2026 interim financial statements, related management’s discussion and analysis, and associated certifications...

VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) (“Monument” or the “Company”) is pleased to announce the results of an additional twenty-three (23) holes that have been received with high gold assay results from the Buffalo Reef/Felda areas and updated drilling activities, under the mine expansion drilling program at the Selinsing Gold Mine, located in Pahang State in the Central Gold Belt of Western Malaysia. Ms. Cathy Zhai, President and CEO of Monument commented: “The drill assay results reported in this announcement underlie the strong potential for resource addition outside of the Life of Mine (“LOM”) and the Expanded Pit Shell. We have deployed more drill rigs and continue to improve the efficiency of exploration.” The Stage 1 and...

Vancouver, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) — NEW EARTH RESOURCES CORP. (CSE: EATH) (“New Earth” or the “Company“) is pleased to announce that it will be conducting a non-brokered private placement (the “Offering”) under which it will raise aggregate gross proceeds of up to $500,000 through the issuance of up to 4,166,667 units (each, a “Unit”) at a price of $0.12 per Unit. Each Unit will consist of one Class A common share (each, a “Share”) and one Share purchase warrant (each, a “Warrant”, entitling the holder to purchase one Share at a price of $0.18 for five years from the date of issuance).  The Company intends to use the proceeds from Offering for general working capital, mineral property exploration and marketing/IR services. The Company may pay finder’s fees and may issue finder’s...

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) — On May 26, 2026, Fitness Champs Holdings Limited (“Fitness Champs Holdings”, “FCHL” or the “Company”) (NASDAQ: FCHL), a distinguished aquatic sports education provider in Singapore, received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), because (i) the stockholders’ equity of the Company of $598,490 as of December 31, 2025, as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, was below the minimum stockholders’ equity requirement of $2,500,000 and (ii) the Company did not, as of May 26, 2026, meet the alternatives standards of market value of listed securities or net income from continuing operations for compliance with Nasdaq Listing Rule 5550(b)(1). Based on the...